“This strategic partnership with IRE ELiT of Belgium is a key move for us in the field of nuclear medicine. IRE ELiT is a global leader in germanium-gallium generator technology. By introducing top-tier international ⁶⁸Ge/⁶⁸Ga generator products, we are breaking through the compliance bottleneck for medical-grade core raw materials in China and accelerating the adoption of ⁶⁸Ga PET imaging technology in clinical settings across the country.”
Recently, Grand Pharma has entered into a deep strategic partnership with the Belgian Institut National des Radioéléments (IRE EliT), a global leader in radioactive isotope technology. Grand Pharma has signed an exclusive agency agreement in China through its wholly-owned subsidiary, Chengdu Purevalley Medical Technology Co., Ltd., becoming the sole supplier and service provider in China for IRE ELiT’s pharmaceutical-grade germanium-gallium generators. Both companies will leverage the respective core strengths in R&D, production, market access, and commercialization to jointly introduce IRE EliT’s globally leading ⁶⁸Ge/⁶⁸Ga generator technology and related regulatory review documents into the Chinese market and promote their widespread application. This initiative marks China’s alignment with the standards of global regulatory authorities such as the FDA and EMA in terms of critical raw material supply for precision diagnostics in the field of nuclear medicine, bringing pharmaceutical-grade germanium-gallium generators that meet international pharmaceutical standards and China’s relevant regulatory requirements to a wide range of Chinese patients.
Through this collaboration, both parties will work together to bring the following to the Chinese market:
- Stable supply of high-tech products: Ensure that Chinese medical institutions can continuously and reliably obtain ⁶⁸Ge/⁶⁸Ga generators that meet international standards, thereby ensuring the smooth implementation of ⁶⁸Ga PET imaging.
- Enhancing the level of nuclear medicine diagnosis and treatment in China: Promoting the popularization and standardized application of ⁶⁸Ga-labeled PET imaging technology in China, enabling more patients to benefit from earlier and more accurate diagnoses.
- Empowering the development of precision medicine: Providing critical evidence for the formulation of individualized treatment strategies, improving treatment outcomes, and optimizing the allocation of medical resources.
- Building the potential for localization: The collaboration will explore the possibility of a localized supply chain, which will be implemented in the future in accordance with regulatory requirements, laying the foundation for enhancing the resilience and safety of the industrial chain.
This collaboration is a powerful alliance based on a shared vision. Grand Pharma will leverage its deep roots and market capabilities in China to handle the registration, localization of the supply chain, marketing, and commercialization of IRE ELiT’s germanium-gallium generator products in China. IRE ELiT will provide its world-class technology, manufacturing processes, and quality assurance to ensure stable supply and exceptional quality, effectively addressing the gap in clinical demand.
“This strategic partnership with IRE ELiT of Belgium is a key move for us in the field of nuclear medicine. IRE ELiT is a global leader in germanium-gallium generator technology. By introducing top-tier international ⁶⁸Ge/⁶⁸Ga generator products, we are breaking through the compliance bottleneck for medical-grade core raw materials in China and accelerating the adoption of ⁶⁸Ga PET imaging technology in clinical settings across the country.”
A representative from Grand Pharma stated, “collaborating with IRE ELiT to bring cutting-edge nuclear medicine technology to China empowers Chinese doctors and patients. Grand Pharma remains committed to its mission of ‘providing quality products and serving the public,’ contributing to the ‘Healthy China’ strategy.”
